Immunotherapy Archives | Oncotarget.net

Oncotarget News

Engineered Bacterial Therapy Activates Immune Response in Cancer Preclinical Studies

October 8, 2025

ACTM-838 showed durable anti-tumor efficacy in multiple murine tumor models and synergized with anti-PD1 therapy in combination.”BUFFALO, NY - October 8, 2025 – A new research paper was published in Volume... read more

Oncotarget

CHEK2 Identified as a Potential Target to Improve Immunotherapy in Solid Tumors

June 20, 2025

Taken together, CHEK2 expression has the potential to predict resistance or non-response to immunotherapy.”BUFFALO, NY - June 20, 2025 – A new review was published in Volume 16 of Oncotarget on... read more

Oncotarget

Rare Pancreatic Cancer Patients Show Strong Response to Immunotherapy

June 17, 2025

Our case series adds to published data from early-phase trials supporting the promise of immunotherapy in some patients with PC.”BUFFALO, NY - June 17, 2025 – A new research paper was... read more

Oncotarget

Immune Side Effects of Liver Cancer Therapy Studied in Latin American Patients

May 23, 2025

This study provides valuable insights into the incidence and impact of irAEs in patients with HCC treated with the combination of atezolizumab and bevacizumab in real-world practice.”BUFFALO, NY - May... read more

Oncotarget

Combining Radiation and Immunotherapy Shows Promise for Bladder Cancer

May 21, 2025

The synergistic mechanisms of radiation therapy and immunotherapy have demonstrated significant potential for enhancing the outcomes of cancer treatment."BUFFALO, NY - May 21, 2025 – A new review was published in... read more

Oncotarget

Clear Scans Can Be Misleading: Residual Cancer Linked to Worse Outcomes

March 21, 2025

SABR is a well-established therapy in both the curative and metastatic setting, however, its ablative potential may not be as high as suggested by radiographic local control rates.”BUFFALO, NY -... read more

Oncotarget

Anti-Correlation Between KLRG1 and PD-1 in Tumor CD8 T Cells

January 21, 2025

The anti-correlation of PD-1 and KLRG1 expression in human tumor infiltrating CD8 T cells suggests the potential for combination therapy supra-additive benefits of anti-PD-1 and anti-KLRG1 therapies.”BUFFALO, NY - January... read more

Oncotarget

Mesenchymal Stem Cells in Cancer Immunotherapy: Promises and Challenges

December 3, 2024

MSCs hold great promise as a therapeutic tool in cancer immunotherapy due to their immunomodulatory properties, tumor-homing abilities, and potential as carriers for delivering therapeutic agents.”BUFFALO, NY - December 3,... read more

Oncotarget

Immunotherapy Success in KRAS G12C Adenosquamous Pancreatic Cancer

November 4, 2024

Here, we present a case of metastatic ASCP with a KRAS G12C mutation refractory to multiple lines of systemic therapy, including platinum-based chemotherapy and targeted inhibition of KRAS G12C.”BUFFALO,... read more

Oncotarget

The Role of Artificial Intelligence in Advancing Intratumoral Immunotherapy

September 19, 2024

We explore how integrating these technologies could revolutionize personalized oncology.”BUFFALO, NY- September 19, 2024 – A new editorial was published in Oncotarget's Volume 15 on September 17, 2024, entitled, “The... read more